First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma

NCT01828034 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Advanced Biliary Tract Carcinoma

Interventions

DRUG: Gemcitabine
DRUG: Cisplatin
DRUG: MEK162

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]